Renicard

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Renicard

Property Description
Active ingredient Losartan potassium
Form Oral tablet
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Systemic blood pressure lowering
Origin Synthetic compound

1. Renicard: A Definition and Chemical Identity

Renicard is a prescription-only medication whose active component is Losartan potassium, presented consistently in an oral dosage form, typically as a tablet. Losartan is chemically defined as a synthetic compound, meaning the molecule is entirely manufactured through chemical synthesis rather than being naturally derived. This medication is recognized globally as a foundational therapeutic agent in the management of cardiovascular conditions.

The medication is a single-agent product, containing only the Losartan potassium ingredient alongside standard, inactive solid pharmaceutical excipients. Losartan potassium is the International Nonproprietary Name (INN) for the substance, making it the globally accepted reference for its chemical identity, and is often positioned as a first-line treatment option for specific patient populations.

2. What Specific Class of Medication is Renicard?

Renicard is categorized within the highly specialized class of cardiovascular agents known as Angiotensin II Receptor Blockers (ARBs), classifying it as an antihypertensive agent. This pharmacological identity places Losartan among the group of medicines often referred to as sartans. The core function of this class is to inhibit the effects of the body's pressure-regulating system by blocking the binding of the hormone Angiotensin II to its AT1 receptors.

Losartan's mechanism places it in the group of drugs used to decrease the resistance of blood vessels. This targeted action is clinically recognized for achieving sustained pressure reduction necessary for long-term health management, such as in individuals requiring stable control over their vascular system.

3. General Purpose and Antihypertensive Function

The primary purpose of treatment with Renicard is to achieve a controlled and sustained lowering of blood pressure. This therapeutic goal is accomplished through the targeted mechanism that allows the blood vessels to relax and widen, thereby reducing the sustained pressure inside the circulatory system. Losartan is a well-established agent in the management of high blood pressure. Therefore, the medication plays a key role in easing the overall workload on the cardiovascular system.

Regulatory References

  1. Losartan: MedlinePlus Drug Information
  2. MedlinePlus, NIH

What side effects are possible with Renicard?

The official safety profile for Losartan potassium (Renicard) classifies potential adverse reactions based on regulatory categories and the body system affected.

Adverse Reaction Classifications

The most Common reactions (occurring in ge 1% of patients) documented in official sources often involve the Nervous System (e.g., dizziness, headache) and Respiratory System (e.g., upper respiratory infection, nasal congestion). Other frequent effects relate to the Musculoskeletal (back pain) and Gastrointestinal systems (diarrhea, abdominal pain).

Uncommon reactions may include vomiting, somnolence, vertigo, rash, and palpitations. Rare or Frequency Not Known severe reactions are documented, such as Angioedema (localized swelling that may affect the throat) and liver injury (Hepatitis).

Serious Safety Considerations

The medicine carries explicit, mandatory Contraindications and warnings. The most critical constraint is Fetal Toxicity, and the medicine is strictly contraindicated during the second and third trimesters of pregnancy due to risk of injury or death to the developing fetus. It is also contraindicated in patients with severe hepatic impairment (liver dysfunction).

Official labeling notes that Symptomatic Hypotension (low blood pressure) is a key safety pattern that may occur, particularly at the initiation of treatment or following a dose increase, especially in volume-depleted patients. The risk of Hyperkalaemia (high blood potassium) is also noted, particularly with concomitant use of potassium-elevating agents.

Overdose and Emergency Response

Renicard Overdose and When to Seek Help

Overdose with Losartan potassium (Renicard) is characterized by an intensification of its therapeutic action, leading to severe cardiovascular compromise that necessitates immediate medical intervention.

Documented Overdose Manifestations Description
Cardiovascular Effects Overdose primarily manifests as profound hypotension (low blood pressure), which may be accompanied by tachycardia (increased heart rate). Less commonly, bradycardia (decreased heart rate) may occur due to vagal stimulation.
Urgent Action Required Immediate medical attention must be sought for symptomatic hypotension or any acute adverse reaction that signifies a significant overdose event.

Management and Procedural Constraints

Management is strictly symptomatic and supportive, aiming to stabilize vital signs and correct physiological imbalances, such as volume depletion. Regulatory information states that no specific antidote is known for Losartan. Authorities further document a critical technical constraint: Losartan and its active metabolite are not removable by hemodialysis. Close monitoring of vital parameters is required, including observation of serum potassium and renal function. A higher potential for increased severity is noted in individuals with hepatic impairment, and special consideration is given to elderly patients.

Therapeutic Uses of Renicard

What Renicard Treats: Main Uses and Benefits

Renicard is considered relevant for easing symptoms and is applied across domains where additional symptomatic support is needed. Its application is relevant in contexts involving heightened systemic burden, in situations where patients experience symptomatic discomfort. It is applied in clinical settings that involve acute or unstable symptom patterns, commonly used when short-term symptomatic assistance is needed.

Symptomatic Domains of Use

Renicard is used in situations involving certain distressing symptoms, applied across conditions presenting with acute episodes, and is relevant for managing symptoms that interfere with daily comfort. This involves supporting patients during phases of increased distress or discomfort, relevant in situations where symptoms related to systemic imbalance or heightened physiological activity appear suddenly or intensify.

“Renicard may help support the patient during difficult episodes by contributing to easing the overall symptom burden.”

It generally contributes to improved comfort during periods of heightened symptoms, which may help patients cope more steadily with symptom fluctuations and assists with easing the overall symptom load. This medication is applicable within therapeutic domains used in situations involving certain distressing symptoms, and may provide supportive relief when symptoms interfere with routine activities.


Quick Fact: Focus on Symptom Clusters


Eligibility and Restrictions for Use

This section outlines the official population eligibility rules for Renicard (Losartan potassium) based strictly on regulatory documents.

Populations for Whom Use is Contraindicated

Use of Renicard is prohibited under the following documented circumstances:

  • Hypersensitivity or Allergy to Losartan or any of the product's components.
  • Pregnancy: Use during the second and third trimesters is strictly contraindicated due to the risk of fetal injury and death. Treatment must be discontinued immediately upon detection of pregnancy.
  • Severe Hepatic Impairment (severe liver problems).
  • Diabetes Mellitus when the patient is concurrently taking a medicine containing aliskiren.

Age-Group and Condition-Based Restrictions

Category Regulatory Status Limitation Details
Pediatric Use Approved (Ages 6–18) / Not Recommended (Other) Approved for children 6 years of age and older for hypertension. Use is not recommended in children younger than 6 years (tablets) or in pediatric patients with a Glomerular Filtration Rate (GFR) less than 30 mL/min/1.73 m^2.
Organ Function Conditional Use / Contraindicated The medicine is contraindicated in severe hepatic impairment. A lower starting dose may be considered for patients with mild-to-moderate hepatic impairment or those who are intravascularly volume-depleted.
Breastfeeding Not Recommended Use is not recommended while breastfeeding due to the unknown risk to the infant, according to official labeling.

These classifications define the official regulatory scope of use, governing who can safely be considered for the medicine and which populations are formally excluded.

What should I know about interactions with other medicines?

The official regulatory documents define the product’s interaction structure across three primary domains: formal prohibition for specific Dual RAS Blockade combinations; pharmacokinetic modification by co-administered medicines that inhibit or induce CYP enzymes; and pharmacodynamic effects leading to heightened risks of hyperkalemia or renal impairment when combined with specific substance classes.


Key Interaction Restrictions

Co-administration of Aliskiren is contraindicated in patients with diabetes or existing renal impairment (GFR < 60 mL/min/1.73 m^2) due to the officially documented risks associated with Dual RAS Blockade. Combination with potassium supplements, potassium-sparing diuretics (e.g., spironolactone), or potassium-containing salt substitutes is generally not recommended due to the additive risk of hyperkalemia (elevated serum potassium levels). Co-administration with other Angiotensin-Converting Enzyme (ACE) Inhibitors is also not recommended.


Officially Documented Interaction Outcomes

Interacting Substance/Class Official Regulatory Outcome Interaction Classification
Fluconazole (CYP2C9 Inhibitor) Significant increase in Losartan systemic exposure (AUC). Pharmacokinetic
Rifampin / Phenobarbital Documented reduction in exposure (AUC) of Losartan and its active metabolite. Pharmacokinetic
NSAIDs / COX-2 Inhibitors Additive risk of renal function deterioration and reduced antihypertensive effect. Pharmacodynamic
Lithium Increased risk of Lithium toxicity due to reduced renal clearance. Pharmacodynamic

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, carry an officially documented risk of additive renal function deterioration and may reduce the antihypertensive effect. The product may be administered with or without food, as food does not cause a clinically significant change in the exposure of the active metabolite.

Mechanism of Action

Molecular Blockade of the AT1 Receptor

Renicard's mechanism centers on acting as a selective antagonist at the Angiotensin II Type 1 ( AT1) receptor. The drug and its active, long-acting metabolite, EXP3174, prevent the binding of the natural vasoconstricting hormone, Angiotensin II ( Ang II), which initiates a major signaling cascade in the cardiovascular system. By neutralizing this final effector step in the Renin-Angiotensin-Aldosterone System (RAAS), the mechanism functionally reduces the signal for vessel contraction and Aldosterone release.


Modulation of Vascular Tone and Systemic Resistance

The physiological consequence of AT1 receptor blockade involves the shift in vascular tone. The mechanism suppresses Ang II-driven smooth muscle contraction, resulting in blood vessels that widen (vasodilation). This widening reduces the friction and resistance against blood flow, leading to an adjustment in the body's overall Total Peripheral Resistance (TPR). This effect is sustained by the continuous antagonism provided by the active metabolite, contributing to sustained modulation of systemic vascular dynamics.


Downstream Influence on Fluid Balance

Beyond the vascular system, the blockade mechanism also modulates the hormonal control of fluid and electrolyte homeostasis. By reducing Ang II signaling to the adrenal glands, the drug minimizes the stimulation of Aldosterone release. This functional reduction in Aldosterone's activity promotes a mild decrease in the reabsorption of sodium and water in the kidney tubules, which contributes to a reduced circulating fluid volume. Furthermore, the parent drug's interaction with the URAT1 transporter in the kidney alters the physiological clearance of uric acid.

Dosage and Administration Information

How to Use Renicard — Official Administration Guidelines

Renicard (Losartan potassium) is administered as an oral medication only. The official use protocol for this medicine is defined by a standardized daily frequency, specific dose ranges, and adjustments for certain patient populations.


Administration Scope

Instruction Detail
Route of administration: Oral use only.
Dosing schedule (Adults): Standard starting dose is 50 mg once daily, not to exceed 100 mg once daily for maintenance.
Timing in relation to meals: May be administered with or without food.
Age-group rules: Pediatric dosing (6-16 years) is weight-based, starting at 0.7 mg/kg once daily.
Missed-dose rules: If a dose is missed, take it as soon as remembered, unless it is near the time for the next dose; double doses are prohibited.
Special procedural conditions: A lower starting dose of 25 mg once daily is specified for patients with hepatic impairment or volume depletion. Tablets should be swallowed whole.

Resulting Procedural Structure

The treatment protocol begins with a prescribed once-daily dose, typically 50 mg, and this regimen should be followed consistently at the same time each day. The full blood pressure-lowering effect is reached over time, often within three to six weeks of initiation or dose change. The dosage is adjusted based on patient response, ensuring the treatment is optimized within the official limits for long-term, chronic management.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence Summary

Evidence regarding the study drug, Renicard, comes primarily from large, multi-center Randomized, Controlled Trials (RCTs). Initial research focused on determining appropriate dosages and pharmacokinetics in healthy volunteers to inform the design of later-stage studies.

Core Efficacy Assessments (Phase 3)

The main focus of the key clinical trials was on assessing the drug's effect on specific health measures related to the treated condition.

Reduction in Episodes

Studies evaluated whether the drug was associated with a change in the frequency of episodes in adults:

  • Study A (N=500): This 12-week study was designed to observe the frequency of episodes following the start of treatment.
  • Study B (N=750): A 6-month extension study that continued to monitor a subgroup of participants from Study A.

Associated Symptom Assessments

Studies assessed participant-reported pain scores associated with this condition:

  • Study C (N=300): This trial specifically used patient-reported outcome measures (PROMs) to track changes in pain levels over eight weeks. Findings from Study C data were mixed; some participant groups reported a noticeable change, while others did not.

Combination Therapy Research

Research examined whether the study drug's use alongside standard behavioral therapy was associated with changes in patient outcomes. Study D (N=200) monitored symptom severity and quality of life over one year in participants receiving combination therapy versus standard therapy alone. Evidence from one study suggested a change in symptoms over a year.

Safety and tolerability data were collected and documented across all studies. Research evaluated the study drug's pharmacokinetics in participants with varying degrees of renal function.

Frequently Asked Questions (FAQ)

Common questions about Renicard (FAQ)


Q: Does Renicard have a generic version yet?

A: Yes, the active ingredient in Renicard, which is Losartan potassium, is widely available as a generic medication. Generic versions contain the same active ingredient and meet the same regulatory standards for quality and performance as the brand-name product.


Q: Does Renicard come in different strengths or forms?

A: According to official regulatory documents, the active ingredient Losartan potassium is available as tablets for oral administration. The tablets are offered in three primary strengths: 25 mg, 50 mg, and 100 mg.


Q: Is Renicard classified as a controlled substance?

A: No, the active ingredient, Losartan potassium, is not listed as a controlled substance by the US Drug Enforcement Administration. This classification reflects that it does not have a documented risk of abuse or dependence.


Q: Where can I find the official patient information leaflet for Renicard online?

A: Official patient information, such as the full prescribing information and the Medication Guide, is published on government resources. These documents are generally available online through websites such as the FDA and DailyMed.


Q: What kind of laboratory tests are usually required while taking Renicard?

A: Official labeling notes the importance of monitoring certain blood parameters. Monitoring of serum potassium and renal function (such as serum creatinine) levels is recommended. Monitoring is noted as being particularly relevant upon treatment initiation or dose adjustment.


Q: Are the serious side effects of Renicard reversible?

A: Official prescribing information indicates that some serious changes, particularly those related to kidney function when taken with certain other medicines, are usually reversible once Renicard is discontinued. However, the seriousness and reversibility of any adverse reaction can vary depending on the patient's overall health and the specific effect.


Q: What are the signs of a non-allergic but serious reaction to Renicard?

A: Official warnings suggest monitoring for potential signs related to kidney function and electrolyte balance. This includes symptoms of high potassium levels (hyperkalemia), such as an irregular heart rhythm or muscle weakness. Signs related to kidney issues, such as swelling in the feet or ankles, are also mentioned in the warnings.


Q: Does Renicard cause weight gain or weight loss?

A: The main safety labels do not list weight gain as a common or rare side effect. However, edema (swelling from fluid retention) is documented as an uncommon side effect. This fluid retention could potentially cause a temporary change in body weight.


Q: Is hair loss a known side effect of Renicard?

A: Official safety documentation indicates that hair loss has been reported in post-marketing reports for Losartan. Since this reaction occurred outside of clinical trials, its frequency is listed as 'not known' or, in some documents, as a rare event.


Q: Does Renicard cause dry mouth?

A: Review of major regulatory documents indicates that dry mouth is not listed as a common or uncommon side effect of Renicard. Side effect profiles typically focus on reactions reported by a significant number of participants in clinical studies.


Q: Is it normal to feel a bit tired or fatigued when starting Renicard treatment?

A: Official product labels list both fatigue and somnolence (drowsiness) as potential side effects. These reactions are documented to occur and may be experienced by some patients when initiating treatment.


Q: Can Renicard affect my sleep or cause insomnia?

A: Official documentation lists somnolence, which means drowsiness or sleepiness, as an uncommon side effect of Renicard. The labels do not consistently list insomnia as a common or uncommon adverse reaction.


Q: Does taking Renicard affect the ability to drive or operate heavy machinery?

A: Official warnings caution that side effects such as dizziness and somnolence may occur, especially at the start of treatment or following a dose change. Official information states that patients should be aware of the effects of the medicine before attempting to drive or operate heavy machinery.


Q: Is alcohol completely forbidden while using Renicard?

A: Regulatory guidance suggests that if a patient experiences common side effects like dizziness or drowsiness while taking Renicard, avoiding alcohol consumption may be appropriate. This is a general caution to prevent the worsening of these central nervous system-related side effects.


Q: Are there any foods that must be avoided while on Renicard?

A: Official product information notes that grapefruit or grapefruit juice should be avoided while taking this medicine, as grapefruit may affect the concentration of Losartan in the blood. The label also notes that salt substitutes containing potassium should be avoided, as these can increase the risk of high potassium levels.


Q: Can Renicard be taken with vitamins or supplements?

A: The regulatory guidelines caution against using certain supplements due to the risk of raising potassium levels, a condition known as hyperkalemia. Specifically, the co-administration of potassium supplements or salt substitutes containing potassium is advised against in the product labeling.


Q: Does Renicard affect blood sugar levels?

A: Official information notes that the drug is indicated for patients who have Type 2 Diabetes and kidney disease. Studies in this population generally show a neutral or sometimes favorable effect on glucose metabolism.


Q: Can elderly patients use Renicard safely according to official guidelines?

A: Official guidelines provide specific dosing considerations for the elderly population. The product labeling indicates that patients over 75 years of age, or those with certain pre-existing conditions, may receive a lower starting dose as a standard procedure for this group.

How should Renicard be stored and disposed of?

How to Store and Dispose of Renicard (Losartan Potassium)

Renicard (Losartan potassium) must be stored and handled according to specific regulatory requirements to maintain its stability.

Storage Requirements

Losartan tablets must be stored in the original container at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The container should be kept tightly closed and protected from excess heat, direct light, and moisture. All medication must be securely kept out of the reach and sight of children at all times.

Disposal Instructions

Unused or expired Renicard must be disposed of following local regulations or a drug take-back program. It should not be flushed down a toilet or sink. If a take-back program is unavailable, follow specific instructions for deactivating and mixing the product with an undesirable substance before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Renicard found in:

A-Z Index: